# Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

> **NCT00159627** · PHASE2 · COMPLETED · sponsor: **NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 52 (—)

## Conditions studied

- Heart Failure, Congestive

## Interventions

- **DRUG:** KW-3902IV

## Key facts

- **NCT ID:** NCT00159627
- **Lead sponsor:** NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 52 (—)
- **Last updated:** 2008-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00159627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00159627, "Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00159627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*